Supplements

Supplements

Results of the GLAGOV trial

Compared with statins alone, treatment with statins plus the PCSK9 inhibitor evolocumab lowered LDL-C more, produced greater atheroma regression,...

Supplements

CABG: A continuing evolution

CABG is having a resurgence, as minimally invasive approaches, robotics, and hybrid procedures are changing the risk-benefit ratio.

Pages